Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 1006


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • cardiac
  • Medical
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1006

License Grant
The US Licensee and Licensor, and, to the extent appropriate, the Licensee of the Netherlands Antilles, shall jointly collaborate in the Development and Commercialization of the Product and the Legal Activities, using Commercially Reasonable Efforts to Develop the Product, to achieve Legal Clearance, to bring the Product to the market in the U.S. Territory and to Commercialize the Product in the U.S. Territory.

Licensor grants to the Licensee of the Netherlands Antilles during the Term, an exclusive license, without the right to grant sublicenses, under Licensor IP and under Licensor's rights in the Joint Collaboration IP, to Develop, make, have made, use, sell, offer to sell, lease, import and export the Product in the U.S. Territory in the Field, and a non-exclusive license, with no right to grant sublicenses, under the Licensor's IP to make, have made, and use the Product in the Non-U.S. Territory, but only for the purposes of sale of the Product in or into the U.S. Territory; provided, however, that Licensor retains the right to practice, and to grant sublicenses, under Licensor IP and under Licensor's rights in the Joint Collaboration IP in the U.S. Territory in the Field to perform its obligations to the Licensees under this Agreement, including, without limitation, to conduct the Licensor activities under this Agreement and in the Annual Collaboration Plans and make and have made the Product in the U.S. Territory solely for the purposes of sales of the Product in the Field in those countries in the Non-U.S. Territory for which US Licensee does not, during the Non-U.S. Option Period, exercise the Non-U.S. Option, or if US Licensee exercises the Non-U.S. Option within the Non-U.S. Option Period, in those countries in the Non-U.S. Territory for which US Licensee and Licensor do not execute a Non-U.S. Territory Agreement either during the Initial Non-U.S. Territory Negotiation Period.

Licensor grants to either, but not both, of the Licensees the exclusive option to commence negotiations to obtain an exclusive license to Develop and Commercialize the Product in all or part of the Non-U.S. Territory.

The Company entered into a collaboration and License Agreement with another pharma to jointly develop and commercialize enoxaparin sodium injection, a generic version of Lovenox®, a low molecular weight heparin or LMWH.

License Property
Licensor is a biotechnology company with specific expertise in enoxaparin and the science of complex sugars, polysaccharides, their structures, their sequencing, and their characterization.

Product means injectable enoxaparin and any improved injectable form of enoxaparin for which Lovenox®, as defined in the relevant New Drug Application approved as of the Effective Date or any past or future Supplemental New Drug Applications, is the reference listed drug and for which an ANDA could be approved by the FDA, but specifically excluding any Improved Enoxaparin.  

Lovenox® (enoxaparin) is a low molecular weight heparin, or LMWH.

The patents include Rationally Designed Heparinases Derived from Heparinase I and II, and,  System and Method for Notating Polymers, and, Novel Method for Sequence Determination using NMR, and, Methods and Products Related to Low Molecular Weight Heparin, and, The Heparinase Gene from Flavobacterium Heparinum, and, Delta 4, 5 Glycuronidase And Uses Thereof.

Field of Use
Lovenox is used in prophylaxis and treatment of deep vein thrombosis, prophylaxis of ischaemic complications of unstable angina and non-Q-wave myocardial infarction, and the treatment of acute ST-segment elevation myocardial infarction.

The Field means the injectable administration of the Product for any and all medical indications.  Lovenox® (enoxaparin) is used to prevent and treat deep vein thrombosis.

IPSCIO Record ID: 27689

License Grant
The Licensor and the Swiss and US Licensee entered into a letter agreement amending the Collaboration and License Agreement relating to, among other things, the development and commercialization of Enoxaparin Sodium Injection.
License Property
Enoxaparin Sodium Injection, a generic version of Lovenox, an anti-coagulant drug used for multiple indications including prevention of deep vein thrombosis, a potentially deadly blood clotting condition.
Field of Use
The Licensee specializes in generic pharma.

IPSCIO Record ID: 243476

License Grant
This letter details the sales terms of the enoxoparin sodium injection product.

Pursuant to a separate agreement relating to the development and commercialization of enoxaparin, and, to characterize the generic enoxaparin for the purpose of obtaining regulatory approval.

Thereafter, Licensee incorporated the technology of the University into release testing of unfractionated heparin used in the manufacture of generic enoxaparin.

License Property
The University and Licensee hereby acknowledge that the enoxaparin product approved by the FDA in July 2010 constitutes a Licensed Product.

Enoxaparin is an anticoagulant that helps prevent the formation of blood clots.

Field of Use
Enoxaparin sodium is an anticoagulant medication. It is used to treat and prevent deep vein thrombosis and pulmonary embolism including during pregnancy and following certain types of surgery.

IPSCIO Record ID: 260415

License Grant
The University grants for the Term a worldwide license to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products and to develop and perform Licensed Processes, which the parties acknowledge may result in the identification of discovered products under Universitys rights.

University grants a first option to add Improvement to the Patent Rights, only in the fields for which exclusive rights, for six months after Company has been notified of the existence of each such Improvement.

License Property
The patent rights are for Heparin and Masspec for Field all but Machines;  for Case 9180 for Field Therapeutics;  for Case 9180 Background to enable and only to enable the practice of patent rights Case 9180; and patent rights Heparinase for Field Heparinase.

Patent titles include Solid-and Solution-Phase Synthesis of Heparin and Other Glycosaminoglycans;  
Synthesis of Oligosaccharides in Solution and on the Solid Support;  Linkers for Synthesis of Oligosaccharides on Solid-Support;  Protecting Groups Useful in the Synthesis of Polysaccharides, Natural Products, and Combinatorial Libraries;  Apparatus and Methods for the Automated Synthesis of Oligosaccharides;   Rationally Designed Heparinases Derived from Heparinase I and II;   System and Method for Notating Polymers;  and, Method for Identifying or Characterizing Properties of Polymeric Units.

Field of Use
The Field all but machines shall mean all fields of use except for the Field Sequencing Machines.

The Field Therapeutics shall mean for internal use in the discovery and development of therapeutic compounds;  and,  the clinical testing, manufacture and sale of therapeutic compounds.  This field shall not include the sale of research reagents or of synthesis machines.

The Field Heparinase shall mean all fields of use except for human use of heparinases as therapeutics in pharmaceutical compositions and except for Field Sequencing Machines.

IPSCIO Record ID: 260416

License Grant
The University grants for the term a license under Universitys patent rights to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products in the Field Sequencing Machines in the Territory.

University grants to Licensee a first option to add improvements to the Patent Rights, only in the fields for which exclusive rights are granted.

License Property
The patents are for Heparinase, Masspec, and Sequencing.

Heparanase, also known as HPSE, is an enzyme that acts both at the cell-surface and within the extracellular matrix to degrade polymeric heparan sulfate molecules into shorter chain length oligosaccharides.

Field of Use
The Field Sequencing Machines shall mean the commercial sale or leasing of sequencing machines, including the performance of sequencing services, but only to the extent such sequencing services are required for the seller or lessor of such a sequencing machine to develop or manufacture such sequencing machine; or performed by the purchaser of such a sequencing machine using the sequencing machine.

Licensee is also utilizing our ability to sequence, or analyze the molecular structure of, sugars, to create generic versions of complex sugar-based drugs, or technology-enabled generic products. Through detailed analysis of the molecular structure of complex sugars, our technology provides a more complete understanding of the roles that sugars play in cellular function, disease and drug action. Based on our understanding of complex sugars, Licensee has developed a diversified pipeline of novel discovery and development candidates and near-term product opportunities.

IPSCIO Record ID: 3640

License Grant
The Company acquired the rights to Aggrastat® Injection (tirofiban hydrochloride) in the U.S. and itsterritories (Puerto Rico, Virgin Islands, and Guam).
License Property
Aggrastat®, a glycoprotein GP IIb/III a receptor antagonist, is used for the treatment of acute coronary syndrome (ACS) including unstable angina, which is characterized by chest pain when one is at rest, and non-Q-wave myocardial infarction (MI).  Aggrastat is a medicine which is used in prevention of a heart attack. Aggrastat contains tirofiban hydrochloride.
Field of Use
The Field of Use apply to the healthcare industry relating to the treatment of ACS.  Acute coronary syndrome (ACS) is usually one of three diseases involving the coronary arteries ST elevation myocardial infarction (30%), non ST elevation myocardial infarction (25%), or unstable angina (38%).
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.